Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

Popular diabetes and weight-loss drugs, including Ozempic (NVO) and Zepbound (LLY), may have a potential link with several ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

The trade threats could reduce exports to the United States and dampen investment in Europe, dealing a blow to growth at a ...

A beloved company that has been part of the fabric of the US and has served hundreds of millions of customers around the ...

Criminals are targeting pharmacies and stealing weight-loss medication in a country with body image insecurities and where ...

With patriotism supercharging consumer spending habits, many are asking if their investments should be local as well ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

Novo Nordisk's semaglutide, which could be the first oral alternative to injectable GLP-1 agonists in type 2 diabetes, has started phase III trials. If it reaches the market, the oral formulation ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...